Hemispherx Biopharma says FDA authorizes study using aspirin and flagship drug ampligen to treat prostate cancer
Hemispherx Biopharma Inc. (NYSEAMERICAN:HEB) announced Monday that federal regulators will allow the company to proceed with a Phase 2 study of combining aspirin and its flagship drug ampligen to treat prostate cancer.
The study authorized by the US Food and Drug Administration will be carried out at the Roswell Park Comprehensive Cancer Center in Buffalo, New York, involving up to 60 patients, the company said in a statement.
“This positive progress in commencing a new prostate cancer clinical trial is just one more step in our focused plan for R&D success,” said CEO Thomas Equels.
READ: Hemispherx sees potential commercialization of flagship drug ampligen for Chronic Fatigue Syndrome
Hemispherx says the study will investigate the effectiveness and safety of aspirin and ampligen with or without drug interferon-alpha 2b (used to treat hepatitis and cancer) compared to no drug treatments in a randomized, three-arm study of patients with prostate cancer before they undergo radical prostatectomy.
The Orlando, Florida-based biotech said aspirin may help to keep the prostate cancer from recurring, while ampligen may stimulate the immune system and interfere with the ability of tumor cells to proliferate. Interferon-alpha 2b may improve the body’s natural response to infections and may slow tumor growth.
It is not yet known how well ampligen, aspirin, and interferon-alpha 2b will work in treating patients with prostate cancer undergoing surgery, the company added.
Hemispherx is studying ampligen to treat ovarian cancer and whether the drug is effective in treating breast cancer in combination with Merck’s (NYSE:MRK) cancer drug keytruda.
Equels said the amount of clinical trials showing progress with ampligen gives the company confidence that “now is the time for us to seek out big pharma partners who share our excitement and enthusiasm for the potential of ampligen.”
Hemispherx’s stocks recently trade up 3% to $0.15 a share.
Contact the author: [email protected]
Follow him on Twitter @PatrickMGraham
Story by ProactiveInvestors
Source: https://www.proactiveinvestors.com/companies/news/220151/hemispherx-biopharma-says-fda-authorizes-study-using-aspirin-and-flagship-drug-ampligen-to-treat-prostate-cancer-220151.html
Anyone can join.
Anyone can contribute.
Anyone can become informed about their world.
"United We Stand" Click Here To Create Your Personal Citizen Journalist Account Today, Be Sure To Invite Your Friends.
Please Help Support BeforeitsNews by trying our Natural Health Products below!
Order by Phone at 888-809-8385 or online at https://mitocopper.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomic.com M - F 9am to 5pm EST
Order by Phone at 866-388-7003 or online at https://www.herbanomics.com M - F 9am to 5pm EST
Humic & Fulvic Trace Minerals Complex - Nature's most important supplement! Vivid Dreams again!
HNEX HydroNano EXtracellular Water - Improve immune system health and reduce inflammation.
Ultimate Clinical Potency Curcumin - Natural pain relief, reduce inflammation and so much more.
MitoCopper - Bioavailable Copper destroys pathogens and gives you more energy. (See Blood Video)
Oxy Powder - Natural Colon Cleanser! Cleans out toxic buildup with oxygen!
Nascent Iodine - Promotes detoxification, mental focus and thyroid health.
Smart Meter Cover - Reduces Smart Meter radiation by 96%! (See Video).
| Online: | |
| Visits: | 1,604,672,721 |
| Stories: | 8,153,871 |
Whistler Blowers, Insiders
